HR Execs on the Move

Conagen

www.conagen.com

 
Conagen is a #syntheticbiology leader, supporting our global partners through #enzymatic and #microbial platforms and #biomanufacturing capabilities.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.conagen.com
  • 15, Deangelo Drive
    Bedford, MA USA 01730
  • Phone: 781.271.1588

Executives

Name Title Contact Details

Similar Companies

Imperial Clinical Research Services

Imperial Clinical Research Services is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

OPK Biotech

OPK Biotech is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthLoop

HealthLoop automates patient engagement to help health providers reduce cost, improve outcomes and deliver a 5-star patient experience. Reassuring guidance each step of the way connects care teams with patients who need it most. HealthLoop enables value-based care for hospitals to monitor at-risk populations, provide outreach when most needed and track patients through an episode of care. Patients rate their doctors with a 5-star experience and providers realize better efficiencies with an automated patient check-in approach. Located in Mountain View, HealthLoop facilitates over 25,000 automated check-ins each month.

Cytiva

We`re the Life Sciences newcomer you already know. Cytiva is bringing our long-standing expertise to the forefront of science, to fuel research, discovery, and development with technologies, instruments, and software. We drive customer-centered innovation in 11 facilities across Asia, Europe and America from idea to commercial development stages.

Imara

Imara Inc. is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain. Imara is developing IMR-687, a highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9i), to treat patients with sickle cell disease. Imara was launched following an 18-month scientific collaboration between orphan drug accelerator Cydan Development and H. Lundbeck A/S.